NEPHROCARE
Nephro Care India Ltd
Each stock's 10,000-path forecast, rendered as light.
Nephro Care India Ltd (NEPHROCARE) Stock Analysis & Case Study
What the numbers say about NEPHROCARE, and the method behind each one.
Nephro Care India Ltd (NEPHROCARE) trades at ₹92,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 26/100.
On the numbers, Nephro Care India Ltd (NEPHROCARE) high-risk on the numbers, a Downstox Snapshot Score of 26/100, weighing premium at 26.9× earnings, ROE of 5.9%, a 45% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
NEPHROCARE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How NEPHROCARE ranks against the 2,982 companies in our screener
- NEPHROCARE's market cap of 152 Cr ranks in the 22nd percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NEPHROCARE's book value of ₹35 ranks in the 26th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NEPHROCARE's promoter holding of 61.7% ranks in the 50th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
We do not hold 3-year profit (PAT) growth, 3-year revenue growth or debt-to-equity ratio figures for NEPHROCARE, as of 14 Aug 2026, so those are not ranked here.
Is NEPHROCARE overvalued? NEPHROCARE P/E vs peers
NEPHROCARE trades at 26.9× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
NEPHROCARE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.1y of NEPHROCARE history (-35%/yr drift, 58%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| NEPHROCARE 2027 | ₹39 | ₹82 | ₹172 | -6% |
| NEPHROCARE 2028 | ₹27 | ₹77 | ₹222 | -12% |
| NEPHROCARE 2029 | ₹20 | ₹72 | ₹256 | -18% |
| NEPHROCARE 2030 | ₹16 | ₹67 | ₹292 | -23% |
| NEPHROCARE 2031 | ₹12 | ₹63 | ₹334 | -28% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability NEPHROCARE goes up, or doubles?
The bull case for NEPHROCARE
- Nephro Care India Ltd is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹256.
The bear case & risks
- NEPHROCARE's P/E of 26.9x is lower than 45% of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NEPHROCARE's return on equity of 5.9% ranks in the 31st percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NEPHROCARE's Piotroski F-Score of 2/8 ranks in the 7th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- High historical volatility (58%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹20.
NEPHROCARE volatility & expected range, how bumpy is the ride?
Over the last 2.1 years NEPHROCARE compounded at -35%/year with annualized volatility of 58%. That volatility implies a 1-year 80% range of ₹39-₹172, the honest backbone behind any single price target.
NEPHROCARE price forecast, the full 60-month probability fan
NEPHROCARE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds NEPHROCARE hits common targets within the simulated horizon?
Full multi-horizon detail on the NEPHROCARE price target & forecast page.
NEPHROCARE Piotroski F-Score: 2/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. NEPHROCARE scores 2/8, weak on the financial-strength checks.
About Nephro Care India Ltd: sector, index & market-cap context
Nephro Care India Ltd (NEPHROCARE) is a small-cap NSE-listed company, with a market capitalisation of ₹152 Cr. See more stocks on our screener.
How the NEPHROCARE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Nephro Care India Ltd's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NEPHROCARE analysis, FAQs
Is Nephro Care India Ltd (NEPHROCARE) a good buy?
On the numbers, Nephro Care India Ltd (NEPHROCARE) high-risk on the numbers, a Downstox Snapshot Score of 26/100, weighing premium at 26.9× earnings, ROE of 5.9%, a 45% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is NEPHROCARE overvalued or undervalued?
NEPHROCARE trades at 26.9× earnings, premium versus the ~22× long-run Nifty average.
What is the NEPHROCARE share price target for 2031?
NEPHROCARE's probability-weighted 2031 median target is ₹63, with an 80% range of ₹12-₹334 (10,000-path Monte-Carlo).
What is the probability NEPHROCARE doubles in 5 years?
The modelled probability of NEPHROCARE reaching ₹175 (2×) within 5 years is 21%.
What is the bull case for NEPHROCARE?
Nephro Care India Ltd is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in NEPHROCARE?
NEPHROCARE's P/E of 26.9x is lower than 45% of the 2,982 NSE companies in our screener, as of 14 Aug 2026. NEPHROCARE's return on equity of 5.9% ranks in the 31st percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026. NEPHROCARE's Piotroski F-Score of 2/8 ranks in the 7th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
More on NEPHROCARE
For information and education only. Downstox is a data and analytics platform, not a SEBI-registered Research Analyst or Investment Adviser. Nothing here is investment advice or a recommendation to buy, sell or hold any security. Any scores, ranks, targets or scenarios are model estimates shown with their method, not forecasts or assured outcomes. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing.